Nothing Special   »   [go: up one dir, main page]

Ratain et al., 2013 - Google Patents

CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality

Ratain et al., 2013

View HTML
Document ID
1841944233723602664
Author
Ratain M
Nakamura Y
Cox N
Publication year
Publication venue
Clinical pharmacology and therapeutics

External Links

Snippet

There has been great controversy over the years regarding the impact of CYP2D6 polymorphisms on the efficacy of tamoxifen in women with breast cancer. The most significant publication to date is the 2009 publication from investigators in Stuttgart and the …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
    • G06F19/18—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
    • G06F19/28—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for programming tools or database systems, e.g. ontologies, heterogeneous data integration, data warehousing or computing architectures
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
    • G06F17/20—Handling natural language data
    • G06F17/21—Text processing
    • G06F17/24—Editing, e.g. insert/delete
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Similar Documents

Publication Publication Date Title
Ratain et al. CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality
Lee et al. Stargazer: a software tool for calling star alleles from next-generation sequencing data using CYP2D6 as a model
Wheeler et al. Cancer pharmacogenomics: strategies and challenges
Pirmohamed Pharmacogenetics: past, present and future
Robinson et al. Genome‐wide and phenome‐wide approaches to understand variable drug actions in electronic health records
Rasmussen‐Torvik et al. High density GWAS for LDL cholesterol in African Americans using electronic medical records reveals a strong protective variant in APOE
Picard et al. Pharmacogenetics-based personalized therapy: levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx)
Teh et al. Clinical relevance of VKORC1 (G‐1639A and C1173T) and CYP2C9* 3 among patients on warfarin
Hill et al. Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer
Frayling Genome-wide association studies: the good, the bad and the ugly
Shah et al. Genetic determinants of glucose-6-phosphate dehydrogenase activity in Kenya
Mukhopadhyay et al. Whole genome sequencing of orofacial cleft trios from the Gabriella Miller Kids First Pediatric Research Consortium identifies a new locus on chromosome 21
Gränsbo et al. Chromosome 9p21 genetic variation explains 13% of cardiovascular disease incidence but does not improve risk prediction
Al-Dewik et al. Genomics and precision medicine: Molecular diagnostics innovations shaping the future of healthcare in Qatar
Seo et al. Deleterious genetic variants in ciliopathy genes increase risk of ritodrine-induced cardiac and pulmonary side effects
Stocco et al. Multilocus genotypes of relevance for drug metabolizing enzymes and therapy with thiopurines in patients with acute lymphoblastic leukemia
Plenge et al. Personalized medicine in rheumatoid arthritis: miles to go before we sleep
Aykan et al. Apa L1 urokinase and Taq 1 vitamin D receptor gene polymorphisms in first-stone formers, recurrent stone formers, and controls in a Caucasian population
Charoenchokthavee et al. Prevalence of CYP2D6* 2, CYP2D6* 4, CYP2D6* 10, and CYP3A5* 3 in Thai breast cancer patients undergoing tamoxifen treatment
Tan et al. Association between Catechol-O-methyltransferase rs4680 (G> A) polymorphism and lung cancer risk
Van Dyke et al. Chromosome 5p region SNPs are associated with risk of NSCLC among women
Matišić et al. Experience with comprehensive pharmacogenomic multi-gene panel in clinical practice: A retrospective single-center study
Huang et al. Acyl-CoA binding domain containing 4 polymorphism rs4986172 and expression can serve as overall survival biomarkers for hepatitis B virus-related hepatocellular carcinoma patients after hepatectomy
Yu et al. Influence of MDM2 polymorphisms on squamous cell carcinoma susceptibility: a meta-analysis
O'Donnell et al. Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants